Adjuvant therapy in prostate cancer: Patient identification and treatment options

S. Syed, A. Tolcher, D. Troyer, J. Furman, R. Leach, I. M. Thompson

Research output: Contribution to journalArticle

Abstract

The recent downward shift in disease stage and patient age at diagnosis has led to an emphasis on definitive local therapy in patients with prostate cancer. However, patients with adverse prognostic factors (non-organ-confined disease, high prostate-specific antigen level, high Gleason score) have a significant risk of treatment failure. With our increasing ability to predict patients at high risk of failure, more patients are likely to receive adjuvant therapy. Adjuvant hormonal therapy extends overall survival after radiotherapy for locally advanced disease, while after surgery improved survival has been demonstrated in patients with node-positive disease. More recently, adjuvant chemotherapy has been investigated.

Original languageEnglish (US)
Pages (from-to)119-126
Number of pages8
JournalUroOncology
Volume4
Issue number3-4
DOIs
StatePublished - Sep 2004

Fingerprint

Prostatic Neoplasms
Therapeutics
Survival
Neoplasm Grading
Adjuvant Chemotherapy
Prostate-Specific Antigen
Treatment Failure
Radiotherapy

Keywords

  • Adjuvant therapy
  • Antiandrogens
  • GnRH agonists
  • Hormonal therapy
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Syed, S., Tolcher, A., Troyer, D., Furman, J., Leach, R., & Thompson, I. M. (2004). Adjuvant therapy in prostate cancer: Patient identification and treatment options. UroOncology, 4(3-4), 119-126. https://doi.org/10.1080/15610950410001732294

Adjuvant therapy in prostate cancer : Patient identification and treatment options. / Syed, S.; Tolcher, A.; Troyer, D.; Furman, J.; Leach, R.; Thompson, I. M.

In: UroOncology, Vol. 4, No. 3-4, 09.2004, p. 119-126.

Research output: Contribution to journalArticle

Syed, S, Tolcher, A, Troyer, D, Furman, J, Leach, R & Thompson, IM 2004, 'Adjuvant therapy in prostate cancer: Patient identification and treatment options', UroOncology, vol. 4, no. 3-4, pp. 119-126. https://doi.org/10.1080/15610950410001732294
Syed, S. ; Tolcher, A. ; Troyer, D. ; Furman, J. ; Leach, R. ; Thompson, I. M. / Adjuvant therapy in prostate cancer : Patient identification and treatment options. In: UroOncology. 2004 ; Vol. 4, No. 3-4. pp. 119-126.
@article{6609742f93dd4c809619ce9302262d7b,
title = "Adjuvant therapy in prostate cancer: Patient identification and treatment options",
abstract = "The recent downward shift in disease stage and patient age at diagnosis has led to an emphasis on definitive local therapy in patients with prostate cancer. However, patients with adverse prognostic factors (non-organ-confined disease, high prostate-specific antigen level, high Gleason score) have a significant risk of treatment failure. With our increasing ability to predict patients at high risk of failure, more patients are likely to receive adjuvant therapy. Adjuvant hormonal therapy extends overall survival after radiotherapy for locally advanced disease, while after surgery improved survival has been demonstrated in patients with node-positive disease. More recently, adjuvant chemotherapy has been investigated.",
keywords = "Adjuvant therapy, Antiandrogens, GnRH agonists, Hormonal therapy, Prostatic neoplasms",
author = "S. Syed and A. Tolcher and D. Troyer and J. Furman and R. Leach and Thompson, {I. M.}",
year = "2004",
month = "9",
doi = "10.1080/15610950410001732294",
language = "English (US)",
volume = "4",
pages = "119--126",
journal = "UroOncology",
issn = "1561-0950",
publisher = "Taylor and Francis Ltd.",
number = "3-4",

}

TY - JOUR

T1 - Adjuvant therapy in prostate cancer

T2 - Patient identification and treatment options

AU - Syed, S.

AU - Tolcher, A.

AU - Troyer, D.

AU - Furman, J.

AU - Leach, R.

AU - Thompson, I. M.

PY - 2004/9

Y1 - 2004/9

N2 - The recent downward shift in disease stage and patient age at diagnosis has led to an emphasis on definitive local therapy in patients with prostate cancer. However, patients with adverse prognostic factors (non-organ-confined disease, high prostate-specific antigen level, high Gleason score) have a significant risk of treatment failure. With our increasing ability to predict patients at high risk of failure, more patients are likely to receive adjuvant therapy. Adjuvant hormonal therapy extends overall survival after radiotherapy for locally advanced disease, while after surgery improved survival has been demonstrated in patients with node-positive disease. More recently, adjuvant chemotherapy has been investigated.

AB - The recent downward shift in disease stage and patient age at diagnosis has led to an emphasis on definitive local therapy in patients with prostate cancer. However, patients with adverse prognostic factors (non-organ-confined disease, high prostate-specific antigen level, high Gleason score) have a significant risk of treatment failure. With our increasing ability to predict patients at high risk of failure, more patients are likely to receive adjuvant therapy. Adjuvant hormonal therapy extends overall survival after radiotherapy for locally advanced disease, while after surgery improved survival has been demonstrated in patients with node-positive disease. More recently, adjuvant chemotherapy has been investigated.

KW - Adjuvant therapy

KW - Antiandrogens

KW - GnRH agonists

KW - Hormonal therapy

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=11144243800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144243800&partnerID=8YFLogxK

U2 - 10.1080/15610950410001732294

DO - 10.1080/15610950410001732294

M3 - Article

AN - SCOPUS:11144243800

VL - 4

SP - 119

EP - 126

JO - UroOncology

JF - UroOncology

SN - 1561-0950

IS - 3-4

ER -